Foghorn Therapeutics (FHTX) Total Non-Current Liabilities (2020 - 2026)

Foghorn Therapeutics' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $298.1 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 6.69% year-over-year to $298.1 million; the TTM figure through Mar 2026 stood at $298.1 million (down 6.69% YoY), while the FY2025 annual figure was $306.0 million, down 7.12% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $298.1 million, down from $306.0 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $415.8 million in Q1 2022, with the low at $294.0 million in Q3 2025.
• The 5-year median for Total Non-Current Liabilities is $367.0 million (2023), against an average of $357.8 million.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities surged 290.36% in 2022, then slipped 10.29% in 2023.
• Foghorn Therapeutics' Total Non-Current Liabilities stood at $404.7 million in 2022, then retreated by 10.29% to $363.1 million in 2023, then retreated by 9.25% to $329.5 million in 2024, then declined by 7.12% to $306.0 million in 2025, then decreased by 2.59% to $298.1 million in 2026.
• Business Quant data shows FHTX's Total Non-Current Liabilities at $298.1 million in Q1 2026, $306.0 million in Q4 2025, and $294.0 million in Q3 2025.